Autoantibodies as diagnostic and prognostic cancer biomarker: Detection techniques and approaches

Autoantibodies produced by the patients’ own immune systems in response to foreign substances are emerging as an attractive biomarker for early detection of cancer. These serum immunobiomarkers are produced in large quantities despite the presence of very less amount of the corresponding antigens, and thus presenting themselves as a novel class of stable and minimally invasive disease biomarkers especially for cancer diagnosis. Although a plethora of research, including conventional molecular biology-based as well as cutting-edge optical and electrochemical strategies (biosensor), have been conducted to detect autoantibodies, most of these strategies are yet to be readily applicable in the off-laboratory settings at clinics. Herein, we detail the biogenesis, diagnostic, prognostic and therapeutic potential of autoantibodies as cancer biomarkers. With the particular emphasis on cutting-edge advances in electrochemistry, optical (surface plasmon resonance)and microfluidics techniques, this review entrusts the unmet needs and challenges of autoantibody detection approaches and provides a future perspective of the presented strategies. We believe this review can potentially guide the researchers towards the development of robust, reliable and sensitive detection strategies for tumor-associated autoantibodies and translation of these biomarkers to real clinical settings for diagnosis and prognosis of cancer.